Infinity Pharma

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced the grant of an inducement stock option award and an inducement restricted stock unit award to Stephane Peluso, Ph.D., the Company's recently hired Chief Scientific Officer, in accordance with Dr. Peluso's emp

Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)

A big investment bank took a new and very bullish view on the stock.

Why Infinity Pharmaceuticals Blasted 38% Higher Today

ironSource Ltd

Akerna Corp

Payoneer Global

Viking Therapeutics

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Blazing Buy-Rated Stocks Under $10 With Gigantic Upside Potential

INFI stock is gaining nearly 50% today after two analysts said yesterday's data-driven drop created a buying opportunity. The post INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plunge appeared first on InvestorPlace.

INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plunge

The stock price of Infinity Pharmaceuticals Inc. (NASDAQ: INFI) increased by over 71% during intraday trading. This is why it happened.

INFI Stock Increases Over 71% Intraday: Why It Happened

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49 patients were enrolled in the MARIO-275 study designed to evaluate it as a combination therapy with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer.

Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which has been shown to reverse a fundamental biologic mechanism of immune suppression in cancer and activate an anti-tumor immune response, today presents data updates from MARIO-275, the Company's randomized, placebo-controlled Phase

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update. Adelene Perkins, Chief Executive Officer and Chair, Infinity Pharmaceuticals, said, “Today we report data indicating that eganelisib r

Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that it will host a key opinion leader webinar on Tuesday, July 27, 2021, at 8 am Eastern Time. The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC cl

Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Dr. Brian Schwartz will present a summary of recent eganelisib clinical data followed by a Q&A session at the Keystone Symposia Precision Oncology: Translating

Infinity to Present at The Keystone Symposia Precision Oncology Meeting

CASI Pharmaceuticals

IsoRay

PDS Biotechnology Corporation

Savara

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q1 2021 Results - Earnings Call Transcript

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which missed the estimate of ($0.12).

Infinity Pharmaceuticals: Q1 Earnings Insights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2021 financial results and provided a corporate update. “2021 is poised to be a landmark year for Infinity with meaningful data updates, building on important data presentations over the last

Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021. Conference call & Webcast Details Date: Thursday,

Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will have a presentation summarizing recent eganelisib clinical data will be followed by a Q&A session at the New York Academy of Sciences' Frontier

Infinity to Present at New York Academy of Sciences' Frontiers in Cancer Immunotherapy 2021

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit which is being held virtually Tuesday, May 4th – Wednesday,

Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit

New Age Beverages

FinVolution Group

Strongbridge Biopharma

5 Stocks to Buy Under $10 With Explosive Upside Potential

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Infinity (INFI) Stock?

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2020 Results - Earnings Call Transcript

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15.00% over the past year to ($0.17), which missed the estimate of ($0.16).

Infinity Pharmaceuticals: Q4 Earnings Insights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2020 financial results and provided an update on the Company, including recent progress with eganelisib. “Over the past months, we have presented transformative data across multiple indications,

Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will present at the Oppenheimer & Co. Annual Healthcare Conference which is being held Tuesday, March 16th – Thursday, March 18th, 2021. Presentatio

Infinity to Present at the Oppenheimer & Co. Annual Healthcare Conference

News for Infinity Pharma Stock (INFI)